自从1980年Ludwig提出非酒精性脂肪肝炎（nonalcoholic steatosis heptitis，NASH）以来，临床发现高达40%的NASH病因不明，且病变隐匿，已存在不同程度的炎症、坏死和纤维化。
基于1个网页-相关网页
非酒精性脂肪性肝炎 NASH ; nonalcoholic steatohepatitis ; nonalcoholic ; Non-alcoholic fatty hepatitis
提出非酒精性脂肪肝炎 nonalcoholic steatosis heptitis
为非酒精性脂肪性肝炎 Nonalcoholic steatohepatitis
和非酒精性脂肪性肝炎 Nonalcoholic steato-hepatitis
了非酒精性脂肪性肝炎 nonalcoholic steatohepatitis
在非酒精性脂肪性肝炎 nonalcoholic steatohepatitis
的非酒精性脂肪性肝炎 nonalcoholic steatohepatitis
鼠非酒精性脂肪性肝炎 non-alcoholic steatohepatitis
对非酒精性脂肪性肝炎 non-alcoholic steatohepatitis
噻唑烷二酮治疗非酒精性脂肪肝炎：继续，停止还是小心前行？
Thiazolidinedione therapy for nonalcoholic steatohepatitis: Go, stop, or proceed with caution?
非酒精性脂肪肝炎(NASH)，是一种与肥胖相关的慢性进展性肝脏疾病。
Nonalcoholic steatohepatitis (NASH) is a chronic progressive liver disease that is strongly associated with obesity.
脂肪性肝病恶化后会很复杂，最严重的是非酒精性脂肪肝炎、肝纤维化、肝硬化。非酒精性脂肪肝会导致肝功能衰竭。
Fatty liver disease can take many forms that vary in severity, with the most severe being nonalcoholic steatohepatitis (NASH), fibrosis and cirrhosis. NAFLD can lead to liver failure.
应用推荐